Safety and Operative Burden of Immediate Lymphatic Reconstruction During Breast Cancer Surgery With Concurrent Breast Reconstruction: A 13‐Year ACS‐NSQIP Analysis
Microsurgery · 2026-12 · 46 (8)
DOI: 10.1002/micr.70327 ↗Abstract
ABSTRACT Background Immediate lymphatic reconstruction (ILR) is increasingly performed during axillary lymph node dissection to reduce breast cancer‐related lymphedema. Prior national studies evaluated broader ALND populations, while the perioperative safety and operative‐duration profile of ILR specifically during concurrent breast reconstruction remains incompletely defined. We evaluated 30‐day safety and total operative duration associated with ILR in women undergoing breast cancer surgery with concurrent reconstruction. Methods We performed a retrospective cohort study using ACS‐NSQIP data from 2012 to 2024. Adult women with breast malignancy undergoing breast extirpative surgery with same‐encounter implant‐based or autologous reconstruction were included. ILR was identified using a published CPT‐based algorithm. The primary outcome was any 30‐day postoperative complication. Secondary outcomes included wound complications, surgical‐site infection (SSI), return to the operating room, readmission, operative time, and length of stay. Temporal efficiency was assessed using an ILR‐by‐year interaction. Results Among 65,437 women, 367 (0.56%) underwent ILR. Use increased from 0.03% in 2012 to 1.57% in 2024. Documented ALND was present in 72.2% of ILR recipients and 18.7% of nonrecipients. ILR was not associated with any 30‐day complication (adjusted odds ratio [aOR] = 0.98; 95% CI = 0.71–1.35; p = 0.898), wound complications (aOR = 1.11; 95% CI = 0.75–1.65; p = 0.597), SSI (aOR = 0.88; 95% CI = 0.56–1.40; p = 0.600), return to the operating room (aOR = 0.92; 95% CI = 0.62–1.37; p = 0.681), or readmission (aOR = 1.05; 95% CI = 0.65–1.70; p = 0.834). ILR was associated with a 90.4‐min longer total operative duration (95% CI = 80.1–100.6; p < 0.001), without a difference in postoperative length of stay (adjusted mean difference, 0.03 days; 95% CI = −0.21 to 0.26; p = 0.832). The operative‐duration difference did not attenuate over time (interaction = 0.44 min/year; 95% CI = −2.89 to 3.78; p = 0.796). Conclusions ILR was not associated with increased adjusted 30‐day morbidity but was associated with longer total operative duration. These findings support short‐term perioperative safety in patients undergoing concurrent reconstruction but do not establish long‐term effectiveness in preventing breast cancer‐related lymphedema.
EUVIMED